Targeting immunosuppressive adenosine in cancer

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Nature Reviews. Cancer

• Publication date

  2017-10-23

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/nrc.2017.86PMID 29059149
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Abstract 5580: Preclinical pharmacodynamics and antitumor activity of AZD4635, a novel adenosine 2A receptor inhibitor that reverses adenosine mediated T cell suppression

  2017cited by this paper
• Abstract CT119: CPI-444, an oral adenosine A2a receptor (A2aR) antagonist, demonstrates clinical activity in patients with advanced solid tumors

  2017cited by this paper
• Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis.

  2017cited by this paper
• Selective activation of anti-CD73 mechanisms in control of primary tumors and metastases

  2017cited by this paper
• Abstract 5577: A novel CD73-blocking antibody reduces production of immunosuppressive adenosine and restores T cell function

  2017cited by this paper
• Abstract 4572: Characterization of the potent and selective A2aR antagonist AB928 for the treatment of cancer

  2017cited by this paper
• Abstract 3970: Targeting the adenosine immunosuppressive pathway for cancer immunotherapy with small molecule agents

  2017cited by this paper
• Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy

  2017cited by this paper
• Protective role of hypoxia‐inducible factor‐1&agr;‐dependent CD39 and CD73 in fulminant acute liver failure

  2017cited by this paper
• MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy.

  2017cited by this paper
• Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer

  2017cited by this paper
• The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets

  2017cited by this paper
• Reassessment of alkaline phosphatase as serum tumor marker with high specificity in osteosarcoma

  2017cited by this paper
• Tumour-derived alkaline phosphatase regulates tumour growth, epithelial plasticity and disease-free survival in metastatic prostate cancer

  2016cited by this paper
• Mesenchymal stromal cells derived from cervical cancer produce high amounts of adenosine to suppress cytotoxic T lymphocyte functions

  2016cited by this paper
• CD73 is associated with poor prognosis in HNSCC

  2016cited by this paper
• Immunogenic cell death in cancer and infectious disease

  2016cited by this paper
• Adenosine-generating ovarian cancer cells attract myeloid cells which differentiate into adenosine-generating tumor associated macrophages – a self-amplifying, CD39- and CD73-dependent mechanism for tumor immune escape

  2016cited by this paper
• CD73-adenosine: a next-generation target in immuno-oncology.

  2016cited by this paper
• Targeting natural killer cells in cancer immunotherapy

  2016cited by this paper
• Phenotypic and functional characteristics of CD39high human regulatory B cells (Breg)

  2016cited by this paper
• Ligand-Independent Adenosine A2B Receptor Constitutive Activity as a Promoter of Prostate Cancer Cell Proliferation

  2016cited by this paper
• Regulatory circuits of T cell function in cancer

  2016cited by this paper
• Extracellular purines, purinergic receptors and tumor growth

  2016cited by this paper
• Cyclic AMP Represents a Crucial Component of Treg Cell-Mediated Immune Regulation

  2016cited by this paper
• The prognostic effects of tumor infiltrating regulatory T cells and myeloid derived suppressor cells assessed by multicolor flow cytometry in gastric cancer patients

  2016cited by this paper
• Lymphatic transport of exosomes as a rapid route of information dissemination to the lymph node

  2016cited by this paper
• Activation of the A2B adenosine receptor in B16 melanomas induces CXCL12 expression in FAP-positive tumor stromal cells, enhancing tumor progression

  2016cited by this paper
• Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action

  2016cited by this paper
• Targeting CD73 in the tumor microenvironment with MEDI9447

  2016cited by this paper
• Overexpression of CD39 in hepatocellular carcinoma is an independent indicator of poor outcome after radical resection

  2016cited by this paper
• A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment

  2016cited by this paper
• Ecto-ATPase CD39 Inactivates Isoprenoid-Derived Vγ9Vδ2 T Cell Phosphoantigens.

  2016cited by this paper
• Transforming Growth Factor-β Signaling Guides the Differentiation of Innate Lymphoid Cells in Salivary Glands.

  2016cited by this paper
• Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses.

  2016cited by this paper
• Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell-Rich Tumor.

  2016cited by this paper
• Adenosine 2B Receptor Expression on Cancer Cells Promotes Metastasis.

  2016cited by this paper
• Ectonucleoside triphosphate diphosphohydrolase-1 (E-NTPDase1/CD39) as a new prognostic marker in chronic lymphocytic leukemia

  2015cited by this paper
• The NAD+ salvage pathway modulates cancer cell viability via p73

  2015cited by this paper
• Myeloid-derived suppressor cells contribute to A2B adenosine receptor-induced VEGF production and angiogenesis in a mouse melanoma model

  2015cited by this paper
• Ecto-5'-nucleotidase expression is associated with the progression of renal cell carcinoma.

  2015cited by this paper
• Loss of CD73-mediated actin polymerization promotes endometrial tumor progression.

  2015cited by this paper
• Immunological mechanisms of the antitumor effects of supplemental oxygenation

  2015cited by this paper
• MicroRNA-128b suppresses tumor growth and promotes apoptosis by targeting A2bR in gastric cancer.

  2015cited by this paper
• CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer

  2015cited by this paper
• CD39 Expression Identifies Terminally Exhausted CD8+ T Cells

  2015cited by this paper
• Overexpression of CD39 and high tumoral CD39⁺/CD8⁺ ratio are associated with adverse prognosis in resectable gastric cancer.

  2015cited by this paper
• CD73 Predicts Favorable Prognosis in Patients with Nonmuscle-Invasive Urothelial Bladder Cancer

  2015cited by this paper
• Metabolic Reprogramming of Immune Cells in Cancer Progression.

  2015cited by this paper
• The expression and clinical significance of CD73 molecule in human rectal adenocarcinoma

  2015cited by this paper
• NAD+-Metabolizing Ectoenzymes in Remodeling Tumor–Host Interactions: The Human Myeloma Model

  2015cited by this paper
• CD73 is associated with poor prognosis in high-grade serous ovarian cancer.

  2015cited by this paper
• CD4+ T cell anergy prevents autoimmunity and generates regulatory T cell precursors

  2015cited by this paper
• Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis

  2015cited by this paper
• Adenosine A2A receptor as a drug discovery target.

  2014cited by this paper
• Extracellular Adenosine-Mediated Modulation of Regulatory T Cells

  2014cited by this paper
• Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor.

  2014cited by this paper
• Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model.

  2014cited by this paper
• Role of TGF-β Signaling in Generation of CD39+CD73+ Myeloid Cells in Tumors

  2014cited by this paper
• Targeting cancer-derived adenosine: new therapeutic approaches.

  2014cited by this paper
• Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity

  2014cited by this paper
• Anti‐CD73 therapy impairs tumor angiogenesis

  2014cited by this paper
• Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment.

  2014cited by this paper
• Systemic oxygenation weakens the hypoxia and hypoxia inducible factor 1α-dependent and extracellular adenosine-mediated tumor protection

  2014cited by this paper
• Consequences of the Lack of CD73 and Prostatic Acid Phosphatase in the Lymphoid Organs

  2014cited by this paper
• Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors

  2013cited by this paper
• IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39

  2013cited by this paper
• Anti-Human CD73 Monoclonal Antibody Inhibits Metastasis Formation in Human Breast Cancer by Inducing Clustering and Internalization of CD73 Expressed on the Surface of Cancer Cells

  2013cited by this paper
• Circulating and Tumor-Infiltrating Myeloid-Derived Suppressor Cells in Patients with Colorectal Carcinoma

  2013cited by this paper
• Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs

  2013cited by this paper
• Overexpression of CD73 in Prostate Cancer is Associated with Lymph Node Metastasis

  2013cited by this paper
• CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer

  2013cited by this paper
• Oncology meets immunology: the cancer-immunity cycle.

  2013cited by this paper
• Extracellular adenosine sensing-a metabolic cell death priming mechanism downstream of p53.

  2013cited by this paper
• Disordered purinergic signaling and abnormal cellular metabolism are associated with development of liver cancer in Cd39/Entpd1 null Mice

  2013cited by this paper
• Extracellular adenosine regulates naive T cell development and peripheral maintenance

  2013cited by this paper
• Hypoxia-Induced Secretion of TGF-β1 in Mesenchymal Stem Cell Promotes Breast Cancer Cell Progression

  2013cited by this paper
• Expression and clinical significance of CD73 and hypoxia-inducible factor-1α in gastric carcinoma.

  2013cited by this paper
• Blockade of A2b adenosine receptor reduces tumor growth and immune suppression mediated by myeloid-derived suppressor cells in a mouse model of melanoma.

  2013cited by this paper
• Soluble Ecto-5′-nucleotidase (5′-NT), Alkaline Phosphatase, and Adenosine Deaminase (ADA1) Activities in Neonatal Blood Favor Elevated Extracellular Adenosine*

  2013cited by this paper
• CD39 and CD73 in immunity and inflammation.

  2013cited by this paper
• HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations.

  2013cited by this paper
• Synergy between the ectoenzymes CD39 and CD73 contributes to adenosinergic immunosuppression in human malignant gliomas.

  2013cited by this paper
• Extracellular generation of adenosine by the ectonucleotidases CD39 and CD73 promotes dermal fibrosis.

  2013cited by this paper
• High expression of CD73 as a poor prognostic biomarker in human colorectal cancer

  2012cited by this paper
• Impairment of adenosine A3 receptor activity disrupts neutrophil migratory capacity and impacts innate immune function in vivo

  2012cited by this paper
• CD73-deficient mice are resistant to carcinogenesis.

  2012cited by this paper
• Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor

  2012cited by this paper
• Adenosine A2B Receptor Blockade Slows Growth of Bladder and Breast Tumors

  2012cited by this paper
• Dendritic cells tolerized with adenosine A₂AR agonist attenuate acute kidney injury.

  2012cited by this paper
• The development and immunosuppressive functions of CD4+ CD25+ FoxP3+ regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway

  2012cited by this paper
• Cancer Exosomes Express CD39 and CD73, Which Suppress T Cells through Adenosine Production

  2011cited by this paper
• NAD+‐metabolizing ecto‐enzymes shape tumor–host interactions: The chronic lymphocytic leukemia model

  2011cited by this paper
• CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis.

  2011cited by this paper
• CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death.

  2011cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• Vascular CD39/ENTPD1 directly promotes tumor cell growth by scavenging extracellular adenosine triphosphate.

  2011cited by this paper
• CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice.

  2011cited by this paper
• Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice

  2011cited by this paper
• Generation of anti‐inflammatory adenosine byleukocytes is regulated by TGF‐β

  2011cited by this paper

• Quinoline carboxylic acid derivatives as potent ectonucleotidase inhibitors.

  2026cites this paper
• Adenosine receptors on the immuno-oncology expressway: TIME, perspectives, and translation

  2026cites this paper
• Activated CD38+ mast cells promote gastric cancer progression by suppressing CD8+ T cell cytotoxic activity through adenosine metabolism.

  2026cites this paper
• Epithelial-mesenchymal plasticity and immunosuppression in canine carcinomas reveals cross-species upregulation of CD109

  2026cites this paper
• Conserved NT5C2 links context-specific behaviors with psychiatric and metabolic risk

  2026cites this paper
• Pharmacokinetics-Driven Optimization of Immunotherapeutic Agents Targeting the Adenosine A2A Receptor (A2AR) and Histone Deacetylases (HDACs).

  2026cites this paper
• CD73 blockade enhances antitumor efficacy of oHSV in solid tumors by increasing macrophage-mediated antigen presentation

  2026cites this paper
• Tumor cell death by ferroptosis contributes to an immunosuppressive tumor microenvironment in syngeneic murine models of cancer

  2026cites this paper
• Expression and prognostic importance of lymphocyte activation gene 3 and CD73 in advanced or metastatic hepatocellular carcinoma

  2026cites this paper
• Design, engineering, and functional evaluation of nanobody-based anti-CD73 for immunogenic cell death induction in chemoresistant colorectal Cancer cell line.

  2026cites this paper
• Communication of bifunctional G-quadruplex chaperone with aptamer for highly selective adenosine signaling by an ESIPT fluorogen.

  2026cites this paper
• Enhanced Immunotherapy Efficacy through Molecularly Imprinted Nanoparticles Co-Targeting Cluster of Differentiation-73 and Programmed Death-Ligand 1.

  2026cites this paper
• Enzymatic and microenvironmental regulation in adenosine metabolism-mediated immunosuppression

  2026cites this paper
• Comprehensive analysis of cellular heterogeneity in the tumor microenvironment reveals TUBG1 as an immunosuppressive regulator in hepatocellular carcinoma

  2025cites this paper
• Next-Generation Immune Checkpoint Inhibitors in Cancer: Mechanisms, Current Clinical Advances, and Future Directions

  2025cites this paper
• Structural Simplification from Tricyclic to Bicyclic Scaffolds: A Long-Term Investigation in the Field of Adenosine Receptor Antagonists

  2025cites this paper
• Crossroads between autoimmunity and cancer: Underlying mechanisms and clinical implications.

  2025cites this paper
• MAGELLAN arms B1 and B3: Durvalumab plus chemotherapy with and without oleclumab in treatment-naïve metastatic non-small-cell lung cancer.

  2025cites this paper
• Phase 1 dose escalation trial of the selective adenosine A2B antagonist PBF-1129 in patients with metastatic non-small cell lung cancer

  2025cites this paper
• Targeting the adenosinergic axis in cancer immunotherapy: Insights into A2A and A2B receptors and novel clinical combination strategies.

  2025cites this paper
• A dual signal amplification strategy of Au@ZIF67 catalysis and target cycle amplification for sensitive chemiluminescence detection of adenosine

  2025cites this paper
• Targeting Myeloid Cells for Cancer Immunotherapy

  2025cites this paper
• Discovery of ORIC-533, an Orally Bioavailable CD73 Inhibitor That Maintains Activity in High AMP Environments to Reverse Tumor Immunosuppression.

  2025cites this paper
• Adenosine/A2AR/PKA signaling regulates HO-1-mediated anti-inflammatory responses during Leishmania donovani infection

  2025cites this paper
• Assessing the impact of CD73 inhibition on overcoming anti-EGFR resistance in glioma cells

  2025cites this paper
• Metabolic-immune axis in the tumor microenvironment: a new strategy for prognostic assessment and precision therapy in DLBCL and FL

  2025cites this paper
• Cascade‐Targeted Nanoparticles for Enhanced Gemcitabine Delivery and Adenosine Metabolism Modulation to Overcome Treatment Resistance in Pancreatic Cancer

  2025cites this paper
• A Critical Review of Immunomodulation in the Management of Inoperable Stage III NSCLC

  2025cites this paper
• Relative adenosine production assay suitable for 2D and 3D tumor cell culture.

  2025cites this paper
• GPCR Antagonism via Antibody-Mediated Rewiring of Receptor Trafficking and Degradation

  2025cites this paper
• Ferroptosis meets cancer immunotherapy: Overcoming the crosstalk challenges through advanced drug delivery strategies

  2025cites this paper
• Assessing Ecto-5’-Nucleotidase/CD73 Expression and Malignancy Parameters in Early- and Late- Passage C6 Glioma Cells

  2025cites this paper
• Association between Ribosomal Protein Gene Dysregulation and Tumor Biodiversity of Hepatocellular Carcinoma

  2025cites this paper
• Leveraging adenosine triphosphate for cancer theranostics

  2025cites this paper
• Zonated Copper‐Driven Breast Cancer Progression Countered by a Copper‐Depleting Nanoagent for Immune and Metabolic Reprogramming

  2025cites this paper
• Bioactive polydopamine nanomedicines-assisted cancer immunotherapy

  2025cites this paper
• Cell Surface‐Tethered Nucleic Acid Therapeutics Program Robust and Tumor‐Responsive Enhancement of Adoptive Cell Therapy

  2025cites this paper
• Macrophage at maternal-fetal Interface: Perspective on pregnancy and related disorders.

  2025cites this paper
• The progress and prospects of targeting the adenosine pathway in cancer immunotherapy

  2025cites this paper
• Revolutionising cancer intervention: the repercussions of CAR-T cell therapy on modern oncology practices

  2025cites this paper
• Metabolites as agents and targets for cancer immunotherapy

  2025cites this paper
• Lung-targeted feedback regulation of the mitochondrial ATP synthesis pathway for orthotopic tumor suppression.

  2025cites this paper
• Lactobacillus-based probiotic cocktail inhibits colitis-associated cancer by altering intestinal metabolism.

  2025cites this paper
• The gut-tumor connection: the role of microbiota in cancer progression and treatment strategies.

  2025cites this paper
• Integrating Metabolic Modulation and Nanomedicine for Cancer Immunotherapy

  2025cites this paper
• Multi-Omics Insights into the Impact of MDH2 on Breast Cancer Progression: A Promising Druggable Target

  2025cites this paper
• P2RY2 is a purinergic immune checkpoint linking extracellular ATP to immune evasion and adaptive resistance to immunotherapy

  2025cites this paper
• Drug-loaded bispecific T cell nanoengager overcomes T cell exhaustion for potent cancer immunotherapy

  2025cites this paper
• Targeting Metabolic Reprogramming in Tumor: From Mechanisms to Precision Immunotherapies

  2025cites this paper
• Adenosine detection technologies: recent advances and applications in the central nervous system

  2025cites this paper
• Post-translational modifications of immune checkpoints: unlocking new potentials in cancer immunotherapy

  2025cites this paper
• Reversing adenosine-mediated immunosuppression in triple-negative breast cancer by synergistic chemo-immunotherapy via stimuli-responsive nanomedicines

  2025cites this paper
• Targeting the Adenosine‐Mediated Metabolic Immune Checkpoint with Engineered Probiotic for Enhanced Chemo‐Immunotherapy

  2025cites this paper
• AMPK-dependent Parkin activation suppresses macrophage antigen presentation to promote tumor progression

  2025cites this paper
• Targeting adenosine enhances immunotherapy in MSS colorectal cancer with EGFRvIII mutation

  2025cites this paper
• "Off-on-off"-based metal-organic framework fluorescent sensor for adenosine triphosphate detection and tumor microenvironment-triggered drug release.

  2025cites this paper
• Adaptation of Natural Killer Cells to Hypoxia: A Review of the Transcriptional, Translational, and Metabolic Processes

  2025cites this paper
• Quantifying CD73 expression after chemotherapy or chemoradiotherapy in esophageal squamous cell carcinoma

  2025cites this paper
• Harnessing the power of tumor-draining lymph nodes: unveiling predictive biomarkers for immune checkpoint inhibitor

  2025cites this paper
• Immune Surveillance and Immune Escape in Cancer: Mechanisms and Immunotherapy

  2025cites this paper
• JUN–ENPP1–cGAS–STING axis mediates immune evasion and tumor progression in bladder cancer

  2025cites this paper
• An Integrated Afterglow and MRI Probe for In Vivo Imaging of ATP in Tumor Metabolism

  2025cites this paper
• Compound 38, a novel potent and selective antagonist of adenosine A2A receptor, enhances arousal in mice

  2025cites this paper
• 32nd Annual GP2A Medicinal Chemistry Conference

  2025cites this paper
• Overcoming multifaceted challenges in cancer treatment: Targeting signal transduction pathways and tumor microenvironment for enhanced therapeutic efficacy

  2025cites this paper
• Monoclonal anti-CD38 therapy in human myeloma: retrospects and prospects

  2025cites this paper
• MnO2-Assisted Photosynthetic Bacteria Interfering with the Adenosine-A2AR Metabolic Pathway to Enhance Tumor Photothermal Immunotherapy.

  2025cites this paper
• Enhanced efficacy of immune checkpoint inhibitors by folate-targeted multifunctional drug through synergistic therapy inducing ferroptosis and immunogenic cell death in bladder cancer

  2025cites this paper
• Tumor-infiltrating myeloid cells; mechanisms, functional significance, and targeting in cancer therapy

  2025cites this paper
• Targeting Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer: Beyond PD-1/PD-L1 Monoclonal Antibodies

  2025cites this paper
• Epithelial-mesenchymal transition orchestrates tumor microenvironment: current perceptions and challenges

  2025cites this paper
• The role of immunotherapy in targeting tumor microenvironment in genitourinary cancers

  2025cites this paper
• Nanomaterials-mediated adenosine pathway inhibition for strengthening cancer immunotherapy

  2025cites this paper
• MGAT1-Guided complex N-Glycans on CD73 regulate immune evasion in triple-negative breast cancer

  2025cites this paper
• Detection of Tumor Immunity-Related ENPP1 using AIE-active Probe QM-AMP

  2025cites this paper
• The role of notch signaling in regulating myeloid-derived suppressor cells: Implications in Cancer and autoimmune diseases.

  2025cites this paper
• Ultrasound-Activatable Nanoprobes for Imaging-Guided Inhibition of Immunosuppressor Production in Tumor Microenvironment

  2025cites this paper
• Design, synthesis and in vitro and evaluation of novel nalidixic acid derivatives as potent ectonucleotidases inhibitors

  2025cites this paper
• Compromised adenosine-A2AR axis contributes to recurrent spontaneous abortion by promoting proinflammatory macrophage polarization.

  2025cites this paper
• Advances in Subclinical and Clinical Trials and Immunosuppressive Therapies in Xenotransplantation

  2025cites this paper
• Extracellular Inosine Induces Anergy in B Cells to Alleviate Autoimmune Hepatitis

  2025cites this paper
• Synergistic blockade of SHP-2 and A2AR signal pathways with targeted nanoparticles restores anti-tumor immunity of CD8+ T cells.

  2025cites this paper
• The Metabolic Orchestration of Immune Evasion in Glioblastoma: From Molecular Perspectives to Therapeutic Vulnerabilities

  2025cites this paper
• Tumor‐Associated Glycan Exploits Adenosine Receptor 2A Signaling to Facilitate Immune Evasion

  2025cites this paper
• Overcoming resistance to immunotherapy by targeting CD38 in human tumor explants

  2025cites this paper
• Tumor-Associated Macrophage in Breast Tumor Microenvironment

  2025cites this paper
• Non-Canonical Functions of Adenosine Receptors: Emerging Roles in Metabolism, Immunometabolism, and Epigenetic Regulation

  2025cites this paper
• Harmine inhibits oxidative phosphorylation, thus regulating the polarization of macrophages mediated by extracellular adenosine in endometriosis.

  2025cites this paper
• Immunomodulation of the Breast Cancer Microenvironment by Tumor-Derived Exosomes: Implications for Immunotherapy

  2025influential citation
• Precision targeting of STING: Challenges, innovations, and clinical outlook for cancer therapy.

  2025cites this paper
• The CD39-CD73-adenosine axis: Master regulator of immune evasion and therapeutic target in pancreatic ductal adenocarcinoma.

  2025cites this paper
• Current strategies for armoring chimeric antigen receptor T-cells to overcome barriers of the solid tumor microenvironment

  2025cites this paper
• Suppressing the Hypoxia‐Adenosinergic Axis by a Tailored Nanoreactor for Enhanced Photothermal Immunotherapy

  2024cites this paper
• Nanocatalysts for modulating antitumor immunity: fabrication, mechanisms and applications.

  2024cites this paper
• HLA-I levels correlate with survival outcomes in response to immune checkpoint inhibitors in non-small cell lung cancer.

  2024cites this paper
• Inosine induces stemness features in CAR-T cells and enhances potency.

  2024cites this paper
• Integrating bulk-RNA sequencing and single-cell sequencing analyses to characterize adenosine-enriched tumor microenvironment landscape and develop an adenosine-related prognostic signature predicting immunotherapy in lung adenocarcinoma

  2024cites this paper
• Recent advances in nanomedicine for metabolism-targeted cancer therapy.

  2024cites this paper
• Adenosine-modulating synthetic high-density lipoprotein for chemoimmunotherapy of triple-negative breast cancer.

  2024cites this paper
• Cancer-associated fibroblast phenotypes are associated with patient outcome in non-small cell lung cancer

  2024cites this paper